Rayyan Therapeutics

Rayyan Therapeutics is an early-stage biotech venture engineering RAY-3PR, a stabilized ADAMTS13 biologic that overcomes the 4.5-hour limit of current stroke therapies. By enhancing stability and enabling safer, later intervention, Rayyan aims to unlock treatment access for millions of stroke patients who currently have no options.